Simvastatin and Amlodipine Interaction: Is It Safe?

Simvastatin (Zocor) and amlodipine (Norvasc) are commonly prescribed together — one for high cholesterol, the other for high blood pressure or angina. However, amlodipine partially inhibits the CYP3A4 enzyme responsible for breaking down simvastatin, causing simvastatin blood levels to rise above expected. This elevation increases the risk of myopathy (muscle damage) and rhabdomyolysis (severe muscle breakdown), prompting the FDA to issue specific guidance restricting the simvastatin dose that can be used when combined with amlodipine.

What Happens When You Combine Them

Simvastatin is an HMG-CoA reductase inhibitor (statin) that is extensively metabolized by CYP3A4 in the intestinal wall and liver before reaching systemic circulation. Amlodipine, a dihydropyridine calcium channel blocker, is itself a substrate and mild inhibitor of CYP3A4. When simvastatin and amlodipine are taken together, amlodipine's partial inhibition of CYP3A4 reduces simvastatin's first-pass metabolism, resulting in higher simvastatin plasma concentrations than the dose alone would suggest.

Pharmacokinetic studies have shown that amlodipine can increase simvastatin exposure by roughly 75% — meaning patients may effectively be experiencing a much higher simvastatin exposure than their prescribed dose implies. At elevated blood levels, simvastatin has a greater likelihood of causing statin-induced myopathy, and in serious cases, rhabdomyolysis — the rapid breakdown of muscle tissue that releases myoglobin into the bloodstream, potentially causing kidney failure.

The FDA reviewed post-marketing case reports of rhabdomyolysis in patients on the combined regimen and updated the simvastatin label with a specific dose restriction when used with amlodipine. This update was part of a broader FDA action addressing several simvastatin drug interactions.

Symptoms to Watch For

• Unexplained muscle pain, aching, tenderness, or cramps
• Muscle weakness — difficulty climbing stairs, rising from a chair, or lifting arms
• Dark, brown, tea-colored, or cola-colored urine (urgent — a sign of rhabdomyolysis)
• Decreased urination or swelling (may indicate kidney involvement)
• Unusual fatigue or fever accompanying muscle symptoms

Who Is Most at Risk

• Patients on higher simvastatin doses — the absolute risk increases proportionally with dose; the FDA restriction is specifically about high-dose simvastatin
• Elderly patients — reduced muscle mass and kidney function amplify susceptibility to myopathy
• People taking additional CYP3A4 inhibitors — other drugs that inhibit CYP3A4 (certain antifungals, antibiotics, heart medications) stack the interaction further
• Patients with hypothyroidism — an independent risk factor for statin-induced myopathy
• Heavy grapefruit consumers — grapefruit also inhibits CYP3A4, compounding amlodipine's effect

What to Do

If you are newly prescribed both: Confirm with your prescriber and pharmacist that your simvastatin dose complies with the FDA guidance for patients also taking amlodipine. Do not adjust your dose on your own.

If you are already taking both: Do not stop either medication abruptly. Speak with your prescriber at your next opportunity to review whether your simvastatin dose is within the recommended limits for co-administration with amlodipine.

Report muscle symptoms promptly: Any unexplained muscle pain or weakness while on a statin — regardless of whether you also take amlodipine — warrants a call to your prescriber. They can order a CK (creatine kinase) blood test to assess muscle damage.

Frequently Asked Questions